You searched for Antibody candidate - Page 8 of 69

In Depth 18 Feb 2025

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

…lurking? At present, there are a number of T cell engagers in the clinic. California-based Janux Therapeutics has two candidates in phase 1 trials. Its lead candidate JANX007 is designed…

February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 31 Mar 2020

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

…rights to develop and commercialize an immuno-oncology drug candidate for an unspecified indication using Numab’s multi-specific antibody platform, MATCH. Antibody-based therapies are becoming increasingly popular in oncology, with Merck’s approved…

March 31, 2020 - 3 minutesmins - By David Kirk

News and Trends 16 Jan 2017

German Antibody for Cancer Diagnostics catches an Australian Eye

…Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the CAIX antigen on clear cell…

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Aug 2019

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

…also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO…

August 29, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 30 Apr 2025

The future of NSCLC treatment: what’s in store for the therapeutic space?

…candidates in the clinic trying to combat this inadequacy. And some of the candidates could be on their way beyond the clinic, as they are being evaluated in late-stage trials….

April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter

Best in Biotech 30 Jan 2017

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

…shown significant advantages over antibody-drug conjugates in preclinical models. Clinical trials for the first candidate are due to start in 2017. Acacia Pharma focuses on conditions caused by aggressive therapies,…

January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

…an antibody that was discovered based on WuXi Bio’s integrated technology platforms, so that Myricx can develop an ADC using the antibody, to target solid tumors, through its NMT-1 platform….

November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter

Best in Biotech 24 Oct 2024

Six biotech companies advancing multiple sclerosis therapies

…debilitating disease. Table of contents Biogen Leading multiple sclerosis drug candidate of Biogen: BIIB091 Biogen is known for its pioneering work in the neuroscience field. It has been discovering and…

October 24, 2024 - 8 minutesmins - By Willow Shah-Neville

In Depth 22 Dec 2022

10 biotech companies to watch in 2023

…candidates — called TCR-T cell therapies — are designed to tackle solid cancers. This is because they are genetically modified to express a custom version of a T-cell protein called…

December 22, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 30 Apr 2018

Record Series B Financing Supports Antibody Cancer Therapy

…of antibody-based therapies for cancer has recently been on the rise in European biotech. For example, late last year Argenx raised €195M to support the clinical development of its antibody…

April 30, 2018 - 2 minutesmins - By Alexander Burik

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

…most common antibody subclass to be used in approved therapies), and has a novel mode of action with a potential to tackle inflammation. It’s also the first antibody to reach…

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 4 Jun 2020

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate…

June 4, 2020 - 4 minutesmins - By Anita Chakraverty

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

German Antibody for Cancer Diagnostics catches an Australian Eye

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

The future of NSCLC treatment: what’s in store for the therapeutic space?

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA

Six biotech companies advancing multiple sclerosis therapies

10 biotech companies to watch in 2023

Record Series B Financing Supports Antibody Cancer Therapy

Two of the Biggest European Biotechs launch Antibody Program together

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!